Semaglutide News and Research

Latest Semaglutide News and Research

A low-energy, high FODMAP diet in prediabetes and diabetes?

Researchers summarize the available knowledge on FODMAPs and suggest that they can play a role in the prevention and treatment of diabetes.

10 Aug 2022

Researchers assess Alzheimer's disease risk and anti-diabetic drugs

In a new study, researchers assessed the genetic variation among targets of Alzheimer's disease risk and anti-diabetic drugs.

3 Aug 2022

IVI successfully completes the '2022 Introductory Course for Biologics Development and Manufacturing'

The International Vaccine Institute (IVI) successfully completed the '2022 Introductory Course for Biologics Development and Manufacturing' on July 29 to train 106 participants from 24 low- and middle-income countries (LMICs) and 32 from the Republic of Korea.

29 Jul 2022

Diabetes patients on Medicare Advantage plans less likely to be prescribed newer, more expensive medicines

While patients with diabetes on Medicare Advantage plans are more likely to receive preventive treatments, they were less likely to be prescribed newer, more expensive medications and were more likely to have higher blood pressure and worse blood glucose control than patients on Medicare Fee-For-Service plans, according to a new study led by a University of Pittsburgh School of Medicine physician-scientist.

7 Jul 2022

Study provides better understanding of the brain pathways that control nausea

Nausea is a bit of a catchall sensation for the human body: the unpleasant sick feeling can hit us as a result of everything from pregnancy or a migraine to eating spoiled food or undergoing chemotherapy.

22 Jun 2022

New weight loss treatment is marked by heavy marketing and modest results

First came the "edible billboard," which appeared last year during the holidays in New York's East Village loaded with cake treats. Then, in late January, came the national marketing campaign, with TV and digital media promoting the idea that trying to lose weight doesn't mean a person can't enjoy eating.

22 Jun 2022

Scientists explore brainstem circuits to find nausea intervention strategies

In a new study, researchers uncovered the organization of nausea-associated brainstem circuits to show that selectively blocking the excitatory neurons responsive to nausea-promoting growth/differentiation factor 15 suppresses nausea-related behaviors.

20 Jun 2022

Synexa Life Sciences Strengthens its Executive Team for Further Growth

Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, announces its plans for growth and the strengthening of its executive team.

From Synexa Life Sciences BV 15 Jun 2022

Syrinx Bioanalytics Acquired by Synexa Life Sciences to Expand Scope of Bioanalysis

Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, has today announced that it has acquired Syrinx Bioanalytics, a bioanalytical CRO based in Turku, Finland.

From Synexa Life Sciences BV 15 Jun 2022

VectorBuilder to expand with $500 million ‘Gene Delivery Research and Manufacturing Campus

VectorBuilder Inc. has announced the construction of a new R&D and manufacturing center in Guangzhou, China.

From VectorBuilder 12 Apr 2022

Machine learning and proteomics predict cardiovascular risk more accurately

An innovative proteomics-based model that predicts the risk of cardiovascular events with higher accuracy than current clinical models.

10 Apr 2022

Diabetes and the mTOR pathway in COVID-19 patients

A new study discusses the possible etiopathogenetic mechanisms associated with diabetes that could enhance the severity of COVID-19.

6 Mar 2022

Researchers discover why patients suffering with hypertension also have diabetes

The long-standing enigma of why so many patients suffering with high blood pressure (known as hypertension) also have diabetes (high blood sugar) has finally been cracked by an international team led by the universities of Bristol, UK, and Auckland, New Zealand.

1 Feb 2022

Study examines the association of race and ethnicity with initiation of newer diabetes medications

Among patients with type 2 diabetes, minority racial/ethnic groups have higher rates of diabetes complications including cardiovascular disease, chronic kidney disease and hypoglycemia (low blood sugar).

25 Jan 2022

DPP4 protein: The connection between severe COVID-19 and diabetes

Researchers explore the relationship between DPP4 and diabetes targets in the management of COVID-19.

17 Jan 2022

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

A new study, posted to the medRxiv* preprint server, has focussed on the development of intranasal prophylaxis against SARS-CoV-2 infection.

11 Jan 2022

Fewer than 1 in 5 U.S. adults with Type 2 diabetes meet targets to reduce heart disease risk

Fewer than 1 in 5 adults with Type 2 diabetes in the U.S. are meeting targets to reduce heart disease risk. Fortunately, available therapies can help when combined with new approaches that address social determinants of health and other barriers to care, according to a new American Heart Association scientific statement published today in the Association's flagship journal Circulation.

10 Jan 2022

Flexibility may maximize the potency of peptides used to treat Type 2 diabetes

A little wiggle room might be just what the doctor ordered. New research suggests that the peptides - short chunks of protein - used to treat Type 2 diabetes may be more effective if they're able to flexibly move back and forth between different shapes.

23 Dec 2021

New study shows inequities in the use of heart disease-protective diabetes drug

A medication typically used for treating diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RA), could also be used to prevent cardiovascular disease and major cardiovascular events, but a new study showed inequities in its use based on race, ethnicity, and socioeconomic status.

17 Dec 2021

CellPort Software joins the Tetra Partner Network to help customers accelerate cell development and manufacturing

TetraScience, the R&D Data Cloud company, announced today that CellPort Software, a SaaS company that digitizes workflows for cell development and manufacturing, has joined the Tetra Partner Network to accelerate delivery of cell-based therapeutics.

From TetraScience, Inc. 15 Dec 2021

Semaglutide News and Research

Latest Semaglutide News and Research

A low-energy, high FODMAP diet in prediabetes and diabetes?

Researchers assess Alzheimer's disease risk and anti-diabetic drugs

IVI successfully completes the '2022 Introductory Course for Biologics Development and Manufacturing'

Diabetes patients on Medicare Advantage plans less likely to be prescribed newer, more expensive medicines

Study provides better understanding of the brain pathways that control nausea

New weight loss treatment is marked by heavy marketing and modest results

Scientists explore brainstem circuits to find nausea intervention strategies

Synexa Life Sciences Strengthens its Executive Team for Further Growth

Syrinx Bioanalytics Acquired by Synexa Life Sciences to Expand Scope of Bioanalysis

VectorBuilder to expand with $500 million ‘Gene Delivery Research and Manufacturing Campus

Machine learning and proteomics predict cardiovascular risk more accurately

Diabetes and the mTOR pathway in COVID-19 patients

Researchers discover why patients suffering with hypertension also have diabetes

Study examines the association of race and ethnicity with initiation of newer diabetes medications

DPP4 protein: The connection between severe COVID-19 and diabetes

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

Fewer than 1 in 5 U.S. adults with Type 2 diabetes meet targets to reduce heart disease risk

Flexibility may maximize the potency of peptides used to treat Type 2 diabetes

New study shows inequities in the use of heart disease-protective diabetes drug

CellPort Software joins the Tetra Partner Network to help customers accelerate cell development and manufacturing

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Semaglutide News and Research

Latest Semaglutide News and Research

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in